775TiPA phase III, randomized, open-label study to compare the efficacy of tislelizumab versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC). (23rd October 2018) - Shen, L; Ajani, J A; Kim, S-B; Van Cutsem, E; Guo, B; Song, J; Paton, V; Kato, K